These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Tumor regression and autoimmunity in cytotoxic T lymphocyte-associated antigen 4 blockade-treated patients. Weber JS Ann Surg Oncol; 2005 Dec; 12(12):957-9. PubMed ID: 16244797 [No Abstract] [Full Text] [Related]
25. Are we entering a new era in melanoma treatment? Lesson from ASCO 2011. Mouawad R; Spano JP; Khayat D Melanoma Res; 2011 Oct; 21(5):377-9. PubMed ID: 21900791 [No Abstract] [Full Text] [Related]
26. Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression. Mosca PJ; Robertson GP Cancer Biol Ther; 2011 Mar; 11(6):581-3. PubMed ID: 21282973 [No Abstract] [Full Text] [Related]
27. Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg. Damian DL; Thompson JF Am J Clin Dermatol; 2011 Dec; 12(6):403-4. PubMed ID: 21967115 [No Abstract] [Full Text] [Related]
28. [Treatment of metastatic melanoma with CTLA4 antibodies]. Hafner C Hautarzt; 2010 Sep; 61(9):808-10. PubMed ID: 20721523 [No Abstract] [Full Text] [Related]
29. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic? Luke JJ; Ott PA Expert Opin Pharmacother; 2013 Dec; 14(18):2457-62. PubMed ID: 24138302 [TBL] [Abstract][Full Text] [Related]
30. Adjuvant therapy for melanoma: a surgical perspective. Sondak VK; Gonzalez RJ; Kudchadkar R Surg Oncol Clin N Am; 2011 Jan; 20(1):105-14. PubMed ID: 21111961 [TBL] [Abstract][Full Text] [Related]
31. [Are immunological treatments beneficial for malignant melanoma of the skin?]. Vihinen P; Vuoristo MS; Hernberg M; Pyrhönen S Duodecim; 2010; 126(14):1701-10. PubMed ID: 20804089 [TBL] [Abstract][Full Text] [Related]
32. [To outwit melanoma with its own tricks]. Bischoff A MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255 [No Abstract] [Full Text] [Related]
33. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. van Rooij N; van Buuren MM; Philips D; Velds A; Toebes M; Heemskerk B; van Dijk LJ; Behjati S; Hilkmann H; El Atmioui D; Nieuwland M; Stratton MR; Kerkhoven RM; Kesmir C; Haanen JB; Kvistborg P; Schumacher TN J Clin Oncol; 2013 Nov; 31(32):e439-42. PubMed ID: 24043743 [No Abstract] [Full Text] [Related]
39. Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Kelderman S; van der Kooij MK; van den Eertwegh AJ; Soetekouw PM; Jansen RL; van den Brom RR; Hospers GA; Haanen JB; Kapiteijn E; Blank CU Acta Oncol; 2013 Nov; 52(8):1786-8. PubMed ID: 23607756 [No Abstract] [Full Text] [Related]
40. Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma. Matsushita S; Krähenbühl L; Otsuka A; Mihic-Probst D; Cheng P; Dummer R; Goldinger SM J Dermatol; 2015 Sep; 42(9):927-8. PubMed ID: 26046957 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]